Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2003
11/13/2003WO2003093274A1 Camptothecin-taxoid conjugates as antimitotic and antitumor agents
11/13/2003WO2003093265A1 Dimeric polycyclic compounds for the treatment of tumors
11/13/2003WO2003093260A1 Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
11/13/2003WO2003093254A1 Semicarbazide derivatives for combating thromboembolic diseases
11/13/2003WO2003093249A1 Thiazolidinones and the use thereof as polo-like kinase inhibitors
11/13/2003WO2003093248A1 Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors
11/13/2003WO2003093242A2 Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
11/13/2003WO2003093241A1 Process for the preparation of 7-substituted-3-quinoline and 3-quinol-4-one carbonitriles
11/13/2003WO2003093238A1 Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
11/13/2003WO2003093235A1 Carboxylic acid amides
11/13/2003WO2003093234A1 Melanocortin receptor ligands
11/13/2003WO2003093231A2 Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity
11/13/2003WO2003092815A1 Method and agents for the prevention, inhibition, and therapy of cancers
11/13/2003WO2003092739A1 Non-viral gene delivery system
11/13/2003WO2003092737A1 Fusions of cytokines and tumor targeting proteins
11/13/2003WO2003092732A1 Ph-sensitive polymer
11/13/2003WO2003092722A1 7-HYDROXY-16α-FLUORO-5-ANDROSTEN-17-ONES AND 7-HYDROXY-16α-FLUORO-5-ANDROSTAN-17-ONES AND DERIVATIVES THEREOF
11/13/2003WO2003092719A2 Methods and compositions for modulating beta-catenin phosphorylation
11/13/2003WO2003092717A1 Cancer immunotherapy
11/13/2003WO2003092709A1 Method for producing preparations rich in tocotrienol
11/13/2003WO2003092708A1 Antitumor agents with the use of hsv
11/13/2003WO2003092699A1 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
11/13/2003WO2003092691A1 Combination of cyclooxygenase-2 inhibitors and thalidomide for the treatment of neoplasia
11/13/2003WO2003092690A1 N-acyl piperidine derivatives for use as melanocortin receptor ligands in the treatment of feeding disorders
11/13/2003WO2003092686A1 Inhibitors of histone deacetylase
11/13/2003WO2003092683A1 Epothilone derivative for the treatment of hepatoma and other cancer diseases
11/13/2003WO2003092678A1 1-substituted imidazole derivatives as nos inhibitors
11/13/2003WO2003092671A1 Method of inhibiting angiogenesis
11/13/2003WO2003092670A1 Bombesin antagonists
11/13/2003WO2003092667A1 Composition for treating cancer containing n,n-dimethylphytosphingosine
11/13/2003WO2003092660A1 Monocompartment osmotic controlled drug delivery system
11/13/2003WO2003092657A1 Microparticles bearing cells and active substances
11/13/2003WO2003092624A2 Use of heat shock proteins to enhance efficacy of antibody therapeutics
11/13/2003WO2003092623A2 Calicheamicin derivative-carrier conjugates
11/13/2003WO2003092613A2 Catechin multimers as therapeutic drug delivery agents
11/13/2003WO2003092608A2 Methionine aminopeptidase-2 inhibitors and methods of use thereof
11/13/2003WO2003092605A2 Protease inhibitors
11/13/2003WO2003092602A2 Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants
11/13/2003WO2003092599A2 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
11/13/2003WO2003092595A2 Tyrosine kinase inhibitors
11/13/2003WO2003092588A2 4-azasteroid derivatives as androgen receptor modulators
11/13/2003WO2003092585A2 Controlled release compositions of estradiol metabolites
11/13/2003WO2003080111A3 Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof
11/13/2003WO2003076465A3 Downregulation of ca 125 tumor antigen and uses thereof
11/13/2003WO2003076417A3 Oxo-azabicyclic compounds
11/13/2003WO2003066621A8 Piperidine derivatives and their use as antagonists of tachykinins
11/13/2003WO2003066034A3 Use of compounds and compositions derived form olives for protecting cells against dna damage
11/13/2003WO2003064447A3 Immune-modulating peptide
11/13/2003WO2003059354A3 Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
11/13/2003WO2003042113A8 Production of cell suspensions
11/13/2003WO2003041563A3 Neurotransmitter balance chemotherapy
11/13/2003WO2003039444A3 Topical use of cytokines and/or chemokines for the treatment of viral or mykotic skin diseases or tumoral diseases
11/13/2003WO2003035008A3 Functionalized stilbene derivatives as improved vascular targeting agents
11/13/2003WO2003033654A3 Direct targeting binding proteins
11/13/2003WO2003033653A3 Affinity enhancement agents
11/13/2003WO2003031407A3 β-LACTAMYL VASOPRESSIN VlaANTAGONISTS
11/13/2003WO2003029436A3 Ul16 binding protein 4
11/13/2003WO2003024448A3 Inhibitors of histone deacetylase
11/13/2003WO2003022871A3 Peptides having a c- terminal hydroxylamino group as inhibitors of dipeptidyl peptidase i
11/13/2003WO2003022806A3 Cbi analogues of cc-1065 and the duocarmycins
11/13/2003WO2003022360A3 Thermotherapy via targeted delivery of nanoscale magnetic particles
11/13/2003WO2003022219A3 Biarylamino purine antiproliferative agents
11/13/2003WO2003020262A3 Use of polyunsaturated fatty acids for intra-arterial injection for selectively occluding blood supplies to neoplasias
11/13/2003WO2003018134A3 Bioadhesive compositions and methods for enhanced mucosal drug absorption
11/13/2003WO2003017939A3 Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
11/13/2003WO2003015703A3 Compositions and methods relating to novel benzodiazepine compounds and targets thereof
11/13/2003WO2003014157A3 Peptides conjugates, their derivatives with metal complexes and use thereof for magnetic resonance imaging (mri)
11/13/2003WO2003012111A3 Conjugates for the modulation of immune responses
11/13/2003WO2003010281A3 Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics
11/13/2003WO2003009778A3 Methods and devices for delivery of therapeutic capable agents with variable release profile
11/13/2003WO2003009773A3 Removable stent and method of using the same
11/13/2003WO2003008005A3 Catheter and implants for the delivery of therapeutic agents to tissues
11/13/2003WO2003006657A3 Gene-regulatory elements for gene therapy, for the prevention and diagnosis of metastases and for the gene therapy of tumours
11/13/2003WO2003000117A3 Detection and treatment of prostate cancer
11/13/2003WO2002102984A3 Hdac9 polypeptides and polynucleotides and uses thereof
11/13/2003WO2002099115A3 Nucleic acid-associated proteins
11/13/2003WO2002098443A3 Stabilised mrna with an increased g/c content and optimised codon for use in gene therapy
11/13/2003WO2002096879A9 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
11/13/2003WO2002088137A9 Pkb-3564 substance with neovascularization inhibitory activity
11/13/2003WO2002066681A3 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
11/13/2003WO2002066648A3 Immunoglobulin superfamily variants expressed in mesenchymal cells and therapeutic uses thereof
11/13/2003WO2002061033A3 Transfection of human embryonic stem cells
11/13/2003WO2002057290A8 Novel fibronectin epitopes and proteinaceous molecules capable of binding said epitopes
11/13/2003WO2002057226A8 68730 and 69112 protein kinase molecules and uses therefor
11/13/2003WO2002056893A8 Novel receptors for $i(helicobacter pylori) and use thereof
11/13/2003WO2002032874A8 Substituted heterocyclic compounds for treating multidrug resistance
11/13/2003WO2002032868A8 2-substituted heterocyclic compounds and their use in treating multidrug resistance
11/13/2003WO2001090313A8 METHODS FOR ASSAYING GENE IMPRINTING AND METHYLATED CpG ISLANDS
11/13/2003WO2001040188A8 Curcumin analogues for treating cancer
11/13/2003US20030213004 Composition comprising ribozyme/monoclonal antibody fusion protein for treating cell proliferative disorders; anticarcinogenic/antiproliferative agents
11/13/2003US20030212276 Process for the preparation of 7-substituted-3 quinolinecarbonitriles
11/13/2003US20030212273 Pyrrolo [2,3-D] pyrimidine compounds
11/13/2003US20030212269 Kinase inhibitor; antitumor agents, psoriasis, skin disorders, antiarthritic agents
11/13/2003US20030212138 Synergistic mixture; analgesics, antiinflammatory agents, cardiovascular disorders, anticancer agents
11/13/2003US20030212121 Antiproliferative agents; anticancer agents; autoimmune diseases; cardiovascular disorders
11/13/2003US20030212113 Novel aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity
11/13/2003US20030212103 Anticancer agents; antiproliferative agents
11/13/2003US20030212097 Osteoporosis, antiarthrtic agents; antitumor agents
11/13/2003US20030212094 Novel cyclic amide derivatives
11/13/2003US20030212093 Imidazonaphthyridines
1 ... 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 ... 2211